A Singapore Firm Bets on a US Biotech: What This Means for Your Cross-Border Structure新加坡公司押注美国生物科技：这对您的跨境架构意味着什么

On June 7, 2026, a filing revealed that Capital Group Investment Management PTE. LTD., a Singapore-based entity, acquired a $2.53 million stake in Royalty Pharma PLC, a US-listed pharmaceutical company. While this news may seems like a routine market transaction, for founders structuring their ventures across the US-China-Hong Kong-Singapore corridor, it serves as a valuable case study in cross-border capital flows, holding company strategy, and tax planning. This signals the tangible pathways through which capital from reputable Asian entities can flow into US businesses, and it highlights the structural considerations that make such investments viable and efficient.

Investment Readiness: Structuring the US Operating Company

For a US-based target to attract institutional capital from Asia, it must be structured in a way that is familiar and efficient for foreign investors. The default choice for most venture-backed and growth-stage companies is the Delaware C-Corp. This structure provides investors with a predictable legal framework, a well-established body of case law, and a clear governance model. Founders expanding from Asia should prioritize establishing their US operating subsidiary as a Delaware C-Corp from the outset. This involves securing an Employer Identification Number (EIN), which can be obtained without an SSN or ITIN via mail or fax though it takes several weeks. More immediately, the US entity must comply with the Corporate Transparency Act by filing a Beneficial Ownership Information (BOI) report with FinCEN, a critical step that new foreign founders frequently overlook. A clean cap table and proper corporate minutes are non-negotiable prerequisites for due diligence, mirroring the standards expected by firms like Capital Group. For those navigating this first-time setup, a thorough Delaware C-Corp setup for foreign founders is an essential resource.

The Holding Company Question: Singapore vs. Traditional Offshore

The news that a Singapore PTE. LTD. is the direct investor is the most instructive part of this announcement. It moves beyond the conventional wisdom of using a Cayman Islands or British Virgin Islands (BVI) holding company. For founders, the choice of a holding jurisdiction has significant implications for tax, reputation, and future strategic flexibility. While BVI/Cayman entities offer low operational overhead and tax neutrality, they are increasingly viewed with regulatory scrutiny. A Singapore holding company, like the one used by Capital Group, offers a compelling alternative. It provides access to one of the world’s most robust tax treaty networks, including the critical US-Singapore tax treaty. This structure can reduce withholding tax on dividends, interest, and royalties flowing from the US. While it requires more substance—such as a local director and physical office—the reputational benefits and treaty access often outweigh the higher compliance costs for serious, long-term builders. Deciding between these options is a core component of effective cross-border corporate structuring for SG and HK founders.

Treaty Optimization: The Power of the US-Singapore Tax Agreement

A Singapore holding company investing in the US does not automatically gain tax benefits; it must qualify under the terms of the US-Singapore tax treaty. The most significant benefit is the reduction or elimination of US withholding tax on outbound dividends. For a portfolio company like Royalty Pharma, this means the Singaporean investor could potentially receive dividend payments with a 0% withholding tax, versus the standard 30% rate for non-treaty entities. To qualify, the Singapore company must meet the treaty’s “Limitation on Benefits” (LOB) clause, which generally requires it to be a publicly traded company, a resident of Singapore with substantial business activities, or owned by qualified residents of Singapore treaty partners. This is not a checkbox exercise; it requires proactive planning to ensure the holding company is structured to meet these tests from day one. Founders who ignore treaty planning could face an unnecessary 30% tax drag on all profits repatriated to their Asian holding entity, a costly mistake that erodes shareholder value. This underscores the critical nature of international tax planning and US-China treaty optimization.

Practical Compliance and Next Steps

What should a founder do next after seeing a deal like this? The immediate action is to evaluate your current or intended structure against this real-world example. A China-outbound founder must first secure outbound direct investment (ODI) approval from MOFCOM/SAFE before capital can be legally deployed to a US subsidiary, a step that can take several months. Singapore and Hong Kong founders face fewer outbound capital controls but must still ensure their holding company is properly capitalized and compliant with ACRA or IRD regulations. Once the US entity is established, annual compliance includes federal and state tax returns, franchise tax payments in Delaware, and the aforementioned BOI report. As your group scales, you will need robust systems for transfer pricing documentation to justify intercompany transactions, such as management service fees or IP licensing. The operational complexity is manageable with the right advisory partner, but proactive planning is far more effective than reactive compliance.

YZ CPA Advisory View

The Capital Group investment highlights a clear trend: sophisticated Asian capital increasingly favors reputable, treaty-optimized holding structures like Singapore Pte. Ltd. over opacity-first offshore shells. For Singapore, Hong Kong, and China-outbound founders, this means building a group structure from day one that is not only tax-efficient but also investment-ready from the perspective of a discerning institutional investor.

中文摘要

新加坡投资实体对美国公司的投资，为跨境创业者提供了关于设立投资准备、选择持股公司司法管辖区以及优化税务协定的宝贵案例。这强调了在扩展至美国时，采用新加坡这样的声誉良好且有税务协定优势的持股结构，对吸引亚洲资本至关重要。